Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats - PubMed

Affiliations

• PMID: 19281809
• DOI: 10.1016/j.ejphar.2009.03.007

Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats

Yoshikazu Fujimori et al. Eur J Pharmacol. 2009.

Abstract

The low-affinity sodium glucose cotransporter (SGLT2) is responsible for most of the glucose reabsorption in the kidney and has been highlighted as a novel therapeutic target for the treatment of diabetes. We discovered sergliflozin etabonate, a novel selective SGLT2 inhibitor, and found that selective inhibition of SGLT2 increased urinary glucose excretion and consequently decreased plasma glucose levels. In this report, we examined the antihyperglycemic effects of sergliflozin etabonate in normal and diabetic rats in comparison with those of a sulfonylurea (gliclazide) and an alpha-glucosidase inhibitor (voglibose). Sergliflozin etabonate increased urinary glucose excretion in a dose-dependent manner, and inhibited the increase in plasma glucose after sucrose loading independently of insulin secretion in normal rats. Sergliflozin etabonate also improved postprandial hyperglycemia in neonatal streptozotocin-induced diabetic rats; whereas gliclazide did not improve it. In rats with mild or moderate streptozotocin-induced diabetes, the degree of the antihyperglycemic effects of sergliflozin etabonate correlated with the severity of the diabetic condition. Sergliflozin etabonate did not affect the plasma glucose level of normal rats as seen with gliclazide. Chronic treatment with sergliflozin etabonate reduced the levels of glycated hemoglobin and fasting plasma glucose, and improved the glycemic response after glucose loading in Zucker fatty rats. In addition, sergliflozin etabonate did not affect the body weight or food intake. These data indicate that sergliflozin etabonate could improve glycemic control without its use resulting in insulin secretion, hypoglycemia, and body weight gain, and may provide a unique approach to the treatment of diabetes.

Similar articles

• Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level.

  Katsuno K, Fujimori Y, Takemura Y, Hiratochi M, Itoh F, Komatsu Y, Fujikura H, Isaji M. Katsuno K, et al. J Pharmacol Exp Ther. 2007 Jan;320(1):323-30. doi: 10.1124/jpet.106.110296. Epub 2006 Oct 18. J Pharmacol Exp Ther. 2007. PMID: 17050778

• Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models.

  Fujimori Y, Katsuno K, Nakashima I, Ishikawa-Takemura Y, Fujikura H, Isaji M. Fujimori Y, et al. J Pharmacol Exp Ther. 2008 Oct;327(1):268-76. doi: 10.1124/jpet.108.140210. Epub 2008 Jun 26. J Pharmacol Exp Ther. 2008. PMID: 18583547

• Long-term treatment with sergliflozin etabonate improves disturbed glucose metabolism in KK-A(y) mice.

  Katsuno K, Fujimori Y, Ishikawa-Takemura Y, Isaji M. Katsuno K, et al. Eur J Pharmacol. 2009 Sep 15;618(1-3):98-104. doi: 10.1016/j.ejphar.2009.07.001. Epub 2009 Jul 15. Eur J Pharmacol. 2009. PMID: 19615995

• [Dapagliflozin, the first SGLT-2 inhibitor in the treatment of type 2 diabetes].

  Albarrán OG, Ampudia-Blasco FJ. Albarrán OG, et al. Med Clin (Barc). 2013 Sep;141 Suppl 2:36-43. doi: 10.1016/S0025-7753(13)70062-9. Med Clin (Barc). 2013. PMID: 24444523 Review. Spanish.

• Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.

  Davidson JA, Kuritzky L. Davidson JA, et al. Postgrad Med. 2014 Oct;126(6):33-48. doi: 10.3810/pgm.2014.10.2819. Postgrad Med. 2014. PMID: 25414933 Review.

Cited by

• Molecular Modeling Studies of Thiophenyl C-Aryl Glucoside SGLT2 Inhibitors as Potential Antidiabetic Agents.

  Sharma MC, Sharma S. Sharma MC, et al. Int J Med Chem. 2014;2014:739646. doi: 10.1155/2014/739646. Epub 2014 Dec 10. Int J Med Chem. 2014. PMID: 25574393 Free PMC article.

• SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function.

  Jurczak MJ, Lee HY, Birkenfeld AL, Jornayvaz FR, Frederick DW, Pongratz RL, Zhao X, Moeckel GW, Samuel VT, Whaley JM, Shulman GI, Kibbey RG. Jurczak MJ, et al. Diabetes. 2011 Mar;60(3):890-8. doi: 10.2337/db10-1328. Diabetes. 2011. PMID: 21357472 Free PMC article.

• Canagliflozin: A Novel SGLT2 Inhibitor for Type 2 Diabetes Mellitus.

  Kaushal S, Singh H, Thangaraju P, Singh J. Kaushal S, et al. N Am J Med Sci. 2014 Mar;6(3):107-13. doi: 10.4103/1947-2714.128471. N Am J Med Sci. 2014. PMID: 24741548 Free PMC article. Review.

• Renal glucose transporters: novel targets for hyperglycemia management.

  Mather A, Pollock C. Mather A, et al. Nat Rev Nephrol. 2010 May;6(5):307-11. doi: 10.1038/nrneph.2010.38. Epub 2010 Mar 30. Nat Rev Nephrol. 2010. PMID: 20351704 Review.

• Synthesis and SAR of Benzisothiazole- and Indolizine-β-d-glucopyranoside Inhibitors of SGLT2.

  Zhou H, Danger DP, Dock ST, Hawley L, Roller SG, Smith CD, Handlon AL. Zhou H, et al. ACS Med Chem Lett. 2010 Jan 29;1(1):19-23. doi: 10.1021/ml900010b. eCollection 2010 Apr 8. ACS Med Chem Lett. 2010. PMID: 24900169 Free PMC article.

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science
  • Ovid Technologies, Inc.

• Medical

  • MedlinePlus Health Information